employing 1D and 2D NMR spectroscopy, enzymatic digestion, and LC-MS was able to definitely identify the contaminant as oversulfated chondroitin sulfate (OSCS). The presence of OSCS within heparin was unexpected and raised the question of whether additional highly sulfated polysaccharides could also be contaminants. To address this question, a systematic study examined structural signatures for persulfonated glycosaminoglycans, including dermatan sulfate, heparin, and so-called side-stream products, using NMR, both mono-and bidimensional, and CE 6 . These studies identified the fact that each persulfonated component, if present, would have a set of unique structural signatures. Finally, mass balance efforts on lots containing OSCS indicated that other persulfonated polysaccharides were not present in suspect lots of 2008 7 .
Nevertheless, the potential for their introduction is possible, especially given that they likely have similar biological activities as OSCS 8 .
Advanced analytical technologies, including most notably multidimensional NMR, have demonstrated the ability to detect a wide range of potential sulfonated polysaccharides if present within heparin 6 . Since initial efforts to detect OSCS in heparin employ a variety of strategies, including HPLC 9, 10 , bioassays 11 , and spectroscopy [12] [13] . However, development of additional, orthogonal assays that can rapidly and sensitively detect the presence of potential contaminants, if present, is warranted. To this end, there have been several reports of potential methods, including ion exchange HPLC 10 , quantitative capillary electrophoresis 14 , inhibition of Taq polymerase in a real-time PCR 15 , a fluorescent receptor array 16 , and use of potentiometric polyanion sensors 17 .
In addition to the above methods, there has been some suggestion that the heparinases, bacterially-derived enzymes that can be used to degrade heparin, may present another strategy towards the detection of OSCS and other persulfonated polysaccharides 5, 18 . To this end, we and others have defined the biochemistry of the heparinases, including their substrate specificity, cofactor requirements, and kinetic parameters [19] [20] [21] [22] [23] . The heparinases specifically cleave the glucosamine (1→4) uronsyl linkage present in heparin/HS and absent from other glycosaminoglycans, including chondroitin sulfate, dermatan sulfate, and hyaluronic acid. As such, we reasoned use of one or more of the heparinases could be used to detect the presence of non-heparin impurities or contaminants in heparin preparations. Indeed, exhaustive digestion of suspect heparin lots results in a reduction of di-, tri-and tetrasaccharide products 5, 18 , consistent with the fact that OSCS is refractory to enzymatic digestion.
In this study, we systematically examined the effect of persulfonated polysaccharides, including OSCS, over(per-)sulfonated dermatan sulfate (OSDS) and over(per-)sulfonated heparin (OSHP) on the enzymatic activity of the heparinases, in the attempt to devise a specific, sensitive assay to detect the presence of contaminants in heparin. We find that persulfonated polysaccharides are efficient inhibitors of the enzymes, especially heparinase I, and inhibit the enzymes in a competitive, reversible manner. We also provide a structural rationale for the observed inhibitory effect of persulfonated GAG substrates on heparinase I by constructing a three-dimensional model of this enzyme with different substrates using the recently solved enzyme-substrate co-crystal structure 24 . Utilizing this understanding, as well as a detailed structural analysis, we devise a rapid, simple assay that can be used to screen heparins for the presence of persulfonated polysaccharides, including OSCS. As compared to other assays, we demonstrate in the present study that exploiting the enzymatic activity and specificity of the heparinases enables the detection of <0.1 wt% of persulfonated polysaccharides in heparin.
MATERIALS AND METHODS
All commercial reagents and kits used directly without further purification. Heparin and heparan sulfate (HS) were obtained from Celsus Laboratories. Heparinases I, II and III were expressed and purified from E. coli as described previously 21, 25 . Persulfonated GAG materials were obtained from R. Linhardt. The molecular weight for OSCS was found to be ~16 kDa, consistent with and based on previous information 26 . The GAG assay kit was obtained from Analysis of heparinase I crystal structure. To enable a structural understanding of the observed biochemical data, the crystal structure of heparinase I in complex with a dodecasaccharide (PDB 3INA) was used as a starting point 24 . Heparinase I in 3INA is a H151A-inactive mutant, therefore, this was first reversed using homology modeling. The dodecasaccharide - corresponding to -2, -1, +1 and +2 positions were considered. Following this, the complex was minimized using the same protocols mentioned above. The structure of OSCS was obtained from PDB 1OFM. The OSCS sequence in the crystal structure ->3GalNAc(4S)β1->4GlcAβ1->3GalNAc(4S) was modified to include additional sulfate groups where possible. The resulting substrate (->3GalNAc(4S,6S)β1->4GlcA(2S,3S)β1->3GalNAc(4S,6S)) was then docked to heparinase I by placing the atoms of the GlcA subunit in place of the IdoA(+1) atoms found in the dodecasaccharide in 3INA. The orientation was manually adjusted to eliminate unfavorable steric contacts with the amino acids of the enzyme active site. The model complex then was minimized using the protocols mentioned above.
HPLC analysis of over sulfated GAG after enzymatic digestion using heparnase as enzyme-Prior
to HPLC analysis, ~ 1mg of heparin or mixture of heparin and OSCS, OSDS, or OSHP were suspended in sodium acetate buffer, pH =7.0, and incubated at 30 o C for about 10 minute, subsequently 1.5 µL (0.35 µM) of heparinase I was added and incubated in a water bath for varying times (from 30 minutes to overnight) to obtain primarily di-and tetrasaccharide products 27 . To determine the inhibition potential of various persulfonated GAGs, OSCS, OSDS or OSHP was spiked into heparin, digested with heparinase I, and analyzed by HPLC. 200 µL (~200 µg)
was injected to the HPLC and digestion products were separated and quantified using two TSK SW 3000 columns (G3000SW, L × I.D. 60 cm × 7.5 mm, 10 µm particle size) connected in an series using an isocartic solvent system of 0.2 M sodium sulfate, pH = 5.0 with UV detection at 232 nm. To confirm peak assignments, a mixture of heparin di and tetrasaccharide standards (Dextra Labs) were used to standardize the column. Three different concentrations of each persulfonated GAG (0.125 %, 0.50 %, and 2.2 %) measured in triplicate were assessed by comparing with the control sample. Triplicate samples were prepared and assessed independently to determine and average value as well as error.
RESULTS

Differential Inhibition of heparinases I, II or III by oversulfated chondroitin sulfate:
Several studies have examined the biochemical and biophysical attributes of the heparinases 19, 20 . Broadly, the heparinases are all lyases, acting through eliminative cleavage to depolymerize polysaccharides containing 1,4-linked β-D-glucuronate or α-L-iduronate residues and α1,4- To understand the effect of OSCS on heparinase I activity, OSCS (1 µg/mL) was added To extend the analysis and to understand the inhibition potential of OSCS towards heparinases II and III, we completed an identical set of experiments with heparinases II and III.
In the present study, with heparin as substrate for heparinase II and HS as substrate for heparinase III, we observe that OSCS is a less efficient inhibitor of heparinases II and III. The IC 50 value and K i for OSCS-based inhibition of heparinase II are found to be 25 µg/mL and 4 µg/mL (~1.5 µM and ~0.3 µM), respectively (Figure 3) , whereas for heparinase III, the observed values are much lower, approximately 700 µg/mL and 250 µg/mL (IC 50 = ~40 µM and K i = ~15 µM), respectively (data not shown). Therefore, based on the above information, we find that the inhibition potential of OSCS decreases in moving from hep I > hep II > hep III. This result suggests closer inspection of the inhibition of hep I by other persulfonated GAGs to determine the best path forward in the design of a sensitive, specific quality control test.
Comparison of the heparinase I inhibition using three different persulfonated GAGs: Previous studies have identified the fact that other GAGs may be present in side-stream heparin,
suggesting there is the potential for contamination with these GAG sources 6, 30 . Specifically, we examined the two most prevalent -OSDS and OSHP. Similar to the studies for OSCS, we determined the inhibitory potential of OSDS and OSHP. The results of these analyses are shown in Table 1 . Inspection of this data and comparison to the data from Figure 2 indicates that heparinase I is potently inhibited by both OSDS and OSHP. For heparinase I, OSDS showed less, but still potent, inhibitory capacity (approximate IC 50 =1.8 µg/mL) compared to OSCS whereas OSHP showed very similar inhibition capacity (approximate IC 50 =0.85 µg/mL). Taken together, these results indicate that the activity of heparinase I is sensitive to wt% levels of ~0.1-0.2% for many persulfonated glycosaminoglycans.
Structural Rationale for Observed Inhibition.
Experimental data demonstrated that the persulfonated GAGs were all competitive inhibitors of heparinase I-III, with heparinase I demonstrating the most marked effect, and that there seemed to be a slight preference for OSCS and OSHP over OSDS. The preference shown by heparinase I in the choice of uronic acid (IdoA over GlcA) at the reducing end (+1 subsite) of its heparin substrate was investigated using the co-crystal structures of heparinase I in complex with different heparin substrates 24 . The heparin from 1AZX docks well into the active site of heparinase I. Comparison between 3INA and the model complex reveals that the directionality of the C5 proton on the +1 subsite, which plays a critical role in the cleavage mechanism, is opposite in the two bound substrates. In the case where there is IdoA in the +1 subsite, the C5 proton faces the side chain of H151, facilitating a hydrogen bond between the Nε2 of Histidine and the C5 proton, thereby enabling proton abstraction ( Figure 4A) . The distance between the Nε2 atom of H151 and the C5 proton is 2.8A.
In contrast, the C5 proton of GlcA (+1) in the model complex faces away from H151 side chain (distance equal to 5.4A) ( Figure 4B ). This prohibits the necessary bond formation resulting in loss of catalytic function. In summary, heparin having GlcA at +1 has an inhibitory effect on heparinase I. 
HPLC as tool to estimate the inhibition potential of over sulfated GAG:
Having developed a robust understanding of the biochemical and structural role of OSCS/OSDS/OSHP mediated inhibition of heparinase I, we sought to develop an assay that could rapidly determine whether a given heparin preparation contained one or more persulfonated compounds. Based on the kinetic analyses (above), persulfonated GAGs strongly inhibit heparinase I. However, a kinetic analysis alone would likely not possess the necessary specificity for the detection of persulfonated contaminants. This is because it is known that heparinase activity can be inhibited by other potential impurities, including metal ions 31 . Therefore, to increase the specificity (and utility) of a enzyme-coupled assay to detect persulfonated GAGs, we completed HPLC profiling of samples obtained from heparinase digestion of either pure heparin (control) or a mixture of heparin and persulfonated GAG. Several types of chromatography have been used to separate and quantify enzymatic digestion products, including strong anion exchange and reverse phase HPLC. However, we reasoned that size-exclusion chromatography (SEC) would be superior to other options since the elution times of size-defined fractions can be easily benchmarked using commercially available standards. In addition, SEC is amenable to both the use of dual detector systems, such as detection by UV absorbance and refractive index. This enables not only direct detection of enzymatic products but also detection of contaminant, if present, and undigested material. Finally, an SEC method does not involve the use of complex buffer or gradient systems, making it ideally suited for a quality control environment.
To standardize the analysis, a mixture of hexasaccharides, as reported previously 32, 33 . Addition of increasing amounts of OSCS resulted in dramatic changes to the profile, both in terms of the quantitative amount (AUC) of di-and tetra-saccharide peaks, which were reduced substantially, as well as the appearance of longer oligosaccharide fragments ( Figure 5) . Notably, and as predicted from the biochemical studies, addition of 0.125 wt% OSCS resulted in a substantial drop in AUC compared to control digestions, and furthermore, increasing the amount of spiked OSCS results in a systematic reduction of the AUC for both the tetra-and disaccharide products. Thus, the LOD of the OSCS detection in heparin is found to be 0.06% of the total substrate used of the enzymatic reaction.
To test whether the inhibition is reversible enzyme was added and the reaction carried out overnight. The overnight reaction shows that more di-and tetra saccharide peaks are formed compared to the reaction carried out for 30 min in presence of OSCS (0.25 %). Furthermore, addition of either OSDS or OSHP showed a similar reduction of peak AUC (Figure 6 ).
Extrapolation of the AUC reduction for both the di-and tetrasaccharides indicates that for OSCS, OSDS, and OSHP, the presence of approximately 2.2-2.5 wt. % of persulfonated GAG results in no detectable levels of di-and tetrasaccharide products.
DISCUSSION
The heparinases have become essential tools in the analysis of heparin and heparan sulfate 34 . A cocktail consisting of heparinases I-III is often use for compositional analysis of heparin and heparin sulfate preparations and in conjunction with either HPLC or capillary electrophoresis has proven to be a powerful tool for the identification and quantification of heparin/HS composition 27, 35 . Furthermore, partial digestion with one or more of the enzymes has been utilized to obtain sequence information 33 . While NMR-based procedures were primarily used in the initial identification of OSCS as the primary contaminant in heparin preparations, enzymatic digestion coupled with HPLC also proved to play an important role.
Since this initial report, limit digests of heparin coupled to LC-MS have been employed to identify the presence of OSCS in heparin 18 .
Many strategies have looked at the use of heparinases I-III as an enzyme "cocktail"
followed by exhaustive depolymerization of heparin and analysis of the products by HPLC or LC-MS 36 . We reasoned that one could take advantage of the inherent substrate specificity of the enzymes to detect contaminants, such as OSCS in a more rapid, and potentially more sensitive manner. Numerous biochemical studies have identified the fact that the heparinases, with overlapping but distinct substrate specificities, more efficiently cleave inter-sugar glycosidic linkages in heparin and HS, leaving intact other glycosaminoglycan linkages, including those present in chondroitin sulfate, dermatan sulfate, and hyaluronic acid 22, 37, 38 . Furthermore, the presence of 3-O sulfation glucosamine is known to inhibit heparinase action [39] [40] , suggesting that persulfonated GAGs may inhibit heparinase action. Given this understanding, in the present work, we completed extensive kinetic analysis to understand the mechanism and extent of OSCS-mediated inhibition of heparinases I-III, and extend this analysis to other persulfonated
GAGs.
The results presented here indicate that OSCS (and by extension OSDS and OSHP) are reversible inhibitors of the heparinases, with OSCS inhibiting heparinase I to a much greater extent (higher potency) than either heparinase II and III. Therefore, our results, presented here, demonstrate that the heparinases, especially heparinase I, can be used as an effective tool to screen heparin. Given the fact that <0.1% OSCS inhibits the enzymatic action of heparinase I
and that the use of a single enzyme instead of a cocktail results in a more controlled digest, requiring less materials and potentially reducing variability, we analyzed the ability of a heparinase I digest to detect the presence of persulfonated materials.
To extend this analysis, we sought to incorporate these findings into a robust, routine quality control test. We first considered whether a kinetic assay, potentially measuring a change in absorbance at 232 nm as a function of time, a measure of enzyme activity, could be used to detect the presence of persulfonated contaminants. However, specificity of this type of assay is not assured since the presence of several components within a heparin preparation could inhibit the heparinase I enzyme, including high salt concentration 19 . Therefore, to improve the specificity of the test and provide a useful quality control tool for heparin, we employed a rapid digestion of heparin with heparinase I, followed by separation and quantification of the products by SEC. The products of enzymatic digestion of heparin by heparinase I have been defined previously 27, 32 , and we find that separation of the products provides additional information, enabling the robust and sensitive detection of persulfonated GAGs, if present. Finally, such an assay system is easily implemented and is able to broadly detect the presence of persulfonated contaminants, making it amenable to use as a screening tool for heparin and low molecular weight heparin preparations.
In summary, the results provided demonstrate that enzymatic tools can be used to quality control heparin. By providing an additional level of specificity and an easily interpreted readout, such an assay should prove useful in the analysis of heparin and assuring its purity and identity. 
